share_log
Moomoo 24/7 ·  03/08 07:03

Amylyx Pharmaceuticals Announced Topline Results From PHOENIX Phase 3 Trial Of AMX0035 For Amyotrophic Lateral Sclerosis, The Study Did Not Meet Its Primary Endpoint Nor Was There Statistical Significance Seen In Secondary Endpoints

Amylyx Pharmicals 公布了 PHOENIX 针对肌萎缩性侧索硬化症的 AMX0035 三期试验的主要结果,该研究未达到其主要终点,次要终点也没有统计学意义

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发